Redox Biol:高半胱氨酸血症患者或可通过运动训练阻止动脉粥样硬化的发展

2017-09-19 Emma MedSci原创

冠状动脉疾病(CAD)是一种常见的心血管疾病类型,在西方很常见,不少人都死于这种疾病。高半胱氨酸血症(HHcy)患者是动脉或静脉血栓栓塞的高危人群,高半胱氨酸血症与动脉粥样硬化之间存在强相关性。

冠状动脉疾病(CAD)是一种常见的心血管疾病类型,在西方很常见,不少人都死于这种疾病。高半胱氨酸血症(HHcy)患者是动脉或静脉血栓栓塞的高危人群,高半胱氨酸血症与动脉粥样硬化之间存在强相关性。研究报道SIRT1(sirtuin 1)在多种疾病中,特别是在心血管系统中,发挥保护作用。

为了探究CAD的治疗策略,研究人员调查了运动训练对HHcy动物细胞凋亡和炎症的影响,并通过调节SIRT1来调查运动是否保护Hhcy诱导的内皮功能障碍。研究结果表明,在Hhcy状态下,运动训练通过SIRT1激活和氧化应激抑制来阻止动脉粥样硬化的发展。

研究人员在C57BL小鼠(每组8只)饮用水中加入1%L-甲硫氨酸(w/w)持续4个月用来诱导HHcy。结果显示,Hhcy抑制SIRT1和AMPK表达并增加NADPH氧化酶活性,血浆MDA,内皮LOX-1和p-p38被Hhcy诱导上调。 NF-κB及其下游分子在Hhcy状态下被激活,促进促炎反应。并且Hhcy引起内皮细胞凋亡,涉及Akt抑制和线粒体依赖性凋亡途径。 运动训练显著抑制Hhcy引起的内皮细胞氧化损伤。此外,使用SIRT1抑制剂EX527后,运动治疗效果被降低。

原始出处:

本文系梅斯医学(MedSci)原创翻译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822232, encodeId=37a2182223237, content=<a href='/topic/show?id=e0e910224067' target=_blank style='color:#2F92EE;'>#高半胱氨酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102240, encryptionId=e0e910224067, topicName=高半胱氨酸血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 25 21:54:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954916, encodeId=869019549161f, content=<a href='/topic/show?id=d5079422460' target=_blank style='color:#2F92EE;'>#运动训练#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94224, encryptionId=d5079422460, topicName=运动训练)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Oct 27 11:54:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767222, encodeId=581c1e672225b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 26 13:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944484, encodeId=8ab0194448444, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Wed Aug 29 15:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917652, encodeId=d9b5191e65278, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 10 23:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822232, encodeId=37a2182223237, content=<a href='/topic/show?id=e0e910224067' target=_blank style='color:#2F92EE;'>#高半胱氨酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102240, encryptionId=e0e910224067, topicName=高半胱氨酸血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 25 21:54:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954916, encodeId=869019549161f, content=<a href='/topic/show?id=d5079422460' target=_blank style='color:#2F92EE;'>#运动训练#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94224, encryptionId=d5079422460, topicName=运动训练)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Oct 27 11:54:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767222, encodeId=581c1e672225b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 26 13:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944484, encodeId=8ab0194448444, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Wed Aug 29 15:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917652, encodeId=d9b5191e65278, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 10 23:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822232, encodeId=37a2182223237, content=<a href='/topic/show?id=e0e910224067' target=_blank style='color:#2F92EE;'>#高半胱氨酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102240, encryptionId=e0e910224067, topicName=高半胱氨酸血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 25 21:54:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954916, encodeId=869019549161f, content=<a href='/topic/show?id=d5079422460' target=_blank style='color:#2F92EE;'>#运动训练#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94224, encryptionId=d5079422460, topicName=运动训练)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Oct 27 11:54:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767222, encodeId=581c1e672225b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 26 13:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944484, encodeId=8ab0194448444, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Wed Aug 29 15:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917652, encodeId=d9b5191e65278, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 10 23:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822232, encodeId=37a2182223237, content=<a href='/topic/show?id=e0e910224067' target=_blank style='color:#2F92EE;'>#高半胱氨酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102240, encryptionId=e0e910224067, topicName=高半胱氨酸血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 25 21:54:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954916, encodeId=869019549161f, content=<a href='/topic/show?id=d5079422460' target=_blank style='color:#2F92EE;'>#运动训练#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94224, encryptionId=d5079422460, topicName=运动训练)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Oct 27 11:54:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767222, encodeId=581c1e672225b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 26 13:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944484, encodeId=8ab0194448444, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Wed Aug 29 15:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917652, encodeId=d9b5191e65278, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 10 23:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822232, encodeId=37a2182223237, content=<a href='/topic/show?id=e0e910224067' target=_blank style='color:#2F92EE;'>#高半胱氨酸血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102240, encryptionId=e0e910224067, topicName=高半胱氨酸血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Mar 25 21:54:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954916, encodeId=869019549161f, content=<a href='/topic/show?id=d5079422460' target=_blank style='color:#2F92EE;'>#运动训练#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94224, encryptionId=d5079422460, topicName=运动训练)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Oct 27 11:54:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767222, encodeId=581c1e672225b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Jul 26 13:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944484, encodeId=8ab0194448444, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Wed Aug 29 15:54:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917652, encodeId=d9b5191e65278, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 10 23:54:00 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
    2018-04-10 柳叶一刀

相关资讯

Am Heart J:疑似CAD患者——CAC评分和SPECT心肌灌注显像后心血管药物的改变

具有正常的心肌灌注显像(MPI)结果的有症状患者中,冠状动脉钙化(CAC)评分对随后心血管药物使用改变的影响还未确定。2017年4月,发表在《Am Heart J》的一项研究评估了疑似冠状动脉疾病的患者中,CAC评分和正常单光子发射计算机断层显像(SPECT)MPI后,阿司匹林和他汀使用的改变。

Redox Biol:SIRT1为冠状动脉疾病治疗提供新参考

CAD,即冠状动脉疾病,是目前主要的心血管事件,这种疾病往往是多种因素综合作用的结果。其中5个重要的风险因素是吸烟、糖尿病、家族性倾向、高血压、血液中异常高的胆固醇水平,还有其他一些因素包括久坐的生活方式、肥胖和心理压力。

2017 ACR适宜性标准:慢性胸痛-高度冠状动脉疾病可能性

高度疑似冠状动脉疾病的胸痛患者,其影像学检查起了重要作用。本文主要概述了高度疑似冠状动脉疾病的慢性胸痛患者的影像学检查,包括心肌影像学检查和冠脉影像学检查。

Redox Biol :SIRT1表达抑制或是冠状动脉疾病患者长期复发性缺血事件高风险的原因之一

研究人员发现在CAD患者来源的单核细胞中,SIRT1表达水平被抑制而乙酰化p53表达水平升高,LOX-1表达和氧化应激增加,引起来自CAD受试者的单核细胞线粒体功能障碍和单核细胞凋亡,引起炎症反应。此外,研究人员还发现,由于SIRT1表达水平抑制,CAD患者的单核细胞对内皮细胞的粘附增加。

Circulation:研究测定冠状动脉疾病风险位点GUCY1A3的功能

已知在全基因组范围内,4q32.1染色体位点与冠状动脉疾病的发病风险密切相关。该位点包含了GUCY1A3,编译可溶性鸟苷酰环化酶(sGC)的α1亚基,sGC是nitric oxide/cGMP信号通路的关键酶。该区域常见变异与冠状动脉发病风险之间联系机制目前尚不清楚。研究人员分别通过定量聚合酶链式反应和免疫印迹法分析基因表达和蛋白质表达。硅片分析坚定了假定的等位基因特异转录因子,并通过等位基因特异

Int J Cardiol:年龄对血小板与淋巴细胞比值与冠状动脉疾病之间相关性的调节作用!

由此可见,在PLR和CAD之间的相关性受年龄的影响。而高PLR是老年高危患者CAD的独立标记,它与年轻早发CAD患者呈负相关。PLR是广泛使用的和廉价的,可以用于识别CAD高风险的患者。